Oligomers count
attyloid’s sFIDA platform technology offers a cutting-edge approach for the quantitative detection of single oligomers and aggregates, which serve as biomarkers of CNS disorders such as Alzheimer’s Disease and Parkinson’s Disease.
![How sFIDA works](https://attyloid.com/wp-content/uploads/2023/10/aggregates_v5.png)
sFIDA technology
aggregates under the spotlight
The sFIDA platform integrates the precision of a selective immunoassay with the superior sensitivity of fluorescence microscopy to count single oligomers, aggregates, and particles. As a result, sFIDA can detect these biomarkers at unprecedented levels of sensitivity and specificity.
applications
we are ![](/wp-content/uploads/2023/10/attyloid-opt-logo-pos-180.svg)
attyloid is an academicy spin-off dedicated to the scientific rigor that the complex fields of protein misfolding and Central Nervous System (CNS) diseases demand. Our research plays a critical role in diagnosing and understanding these diseases and paving the way for innovative therapeutics.
![we are attyloid](https://attyloid.com/wp-content/uploads/2023/10/we-are-attyloid.jpg)